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Juvenile myelomonocytic leukemia (JMML), a rare myelodysplastic/myeloproliferative
neoplasm of early childhood, is characterized by clonal growth of RAS signaling addicted
stem cells. JMML subtypes are defined by specific RAS pathway mutations and display
distinct gene, microRNA (miRNA) and long non-coding RNA expression profiles. Here
we zoom in on circular RNAs (circRNAs), molecules that, when abnormally expressed,
may participate in malignant deviation of cellular processes. CirComPara software was
used to annotate and quantify circRNAs in RNA-seq data of a “discovery cohort”
comprising 19 JMML patients and 3 healthy donors (HD). In an independent set of
12 JMML patients and 6 HD, expression of 27 circRNAs was analyzed by qRT-PCR.
CircRNA-miRNA-gene networks were reconstructed using circRNA function prediction
and gene expression data. We identified 119 circRNAs dysregulated in JMML and 59
genes showing an imbalance of the circular and linear products. Our data indicated also
circRNA expression differences among molecular subgroups of JMML. Validation of a
set of deregulated circRNAs in an independent cohort of JMML patients confirmed the
down-regulation of circOXNAD1 and circATM, and a marked up-regulation of circLYN,
circAFF2, and circMCTP1. A new finding in JMML links up-regulated circMCTP1
with known tumor suppressor miRNAs. This and other predicted interactions with
miRNAs connect dysregulated circRNAs to regulatory networks. In conclusion, this
study provides insight into the circRNAome of JMML and paves the path to elucidate
new molecular disease mechanisms putting forward circMCTP1 up-regulation as a
robust example.
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INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is a rare and
aggressive neoplasm of early childhood with a peak incidence
around 2 years of age and an estimated incidence of
approximately 1–2 per million (Niemeyer et al., 1997). Clonal
growth of an abnormal multipotent hematopoietic stem cell leads
to the characteristic proliferative features, such as monocytosis,
splenomegaly and also a moderately elevated percentage of
myeloblasts, while erythropoiesis and thrombopoiesis are mostly
decreased (Niemeyer, 2014). Typical mutations in NRAS and
KRAS (20–25%), PTPN11 (35%), NF1 (10–15%), or CBL (10–
15%) genes can be found in 90–95% of patients and cause
activation of the RAS signal transduction cascade. Within these
genetically distinct subtypes, clinical and biological heterogeneity
can be observed, from aggressive JMML needing hematopoietic
stem cell transplantation in the majority of patients, to indolent
disease with spontaneous resolution (Locatelli and Niemeyer,
2015). Clinical features such as age, hemoglobin F, platelet
counts (Niemeyer et al., 1997) and gene expression signatures
(Bresolin et al., 2010) were proven to have prognostic value. In
recent years, development of the molecular biology toolbox has
identified secondary mutations (Caye et al., 2015; Stieglitz et al.,
2015; Coppe et al., 2018; Murakami et al., 2018), novel fusion
genes (Lipka et al., 2017; Murakami et al., 2018; Chao et al.,
2020), aberrant genomic DNA methylation (Lipka et al., 2017;
Stieglitz et al., 2017; Murakami et al., 2018; Chao et al., 2020),
and dysregulation in the non-coding transcriptome (microRNA,
miRNA, and long non-coding RNA, lncRNAs, Leoncini et al.,
2016; Hofmans et al., 2018) as molecular mechanisms associated
with JMML pathogenesis and linked to prognostic relevance.
Circular RNAs (circRNAs) are single stranded RNA
molecules with backspliced 3′- and 5′-ends linked in a non-
collinear manner. Acting as miRNA sponges and competitive
endogenous RNAs, circRNAs can indirectly regulate miRNA-
target expression, ultimately controlling key miRNA-involving
axes (Hansen et al., 2013; Li et al., 2015). CircRNAs can also
interact with RNA-binding proteins (Schneider et al., 2016) and
regulate cellular processes (Du et al., 2016). Several circRNAs
were also shown to translate to unique peptides not encoded by
linear transcripts (Legnini et al., 2017; Pamudurti et al., 2017;
Yang et al., 2017). CircRNA-encoded peptides were shown to
function in the regulation of cell differentiation (Legnini et al.,
2017) and cancer progression (Rossi et al., 2019). More and
more, the key role of circRNAs in leukemogenesis is emerging
(Bonizzato et al., 2016; Jamal et al., 2019; Buratin et al., 2020) and
perturbation of circRNA propagates in regulatory networks (Bhat
et al., 2020) and signaling pathways, with pleiotropic effects.
Few studies have investigated circRNA expression in myeloid
malignancies. In acute myeloid leukemia (AML), a role
Abbreviations: JMML, Juvenile Myelomonocytic Leukemia; miRNA, microRNA;
lncRNA, long non-coding RNA; circRNA, circular RNA; RNA-seq, RNA
sequencing; HD, healthy donors; qRT-PCR, Quantitative Reverse Transcription
Polymerase Chain Reaction; HSCT, hematopoietic stem cell transplantation; AML,
Acute Myeloid Leukemia; BM, bone marrow; PB, peripheral blood; CLP, Circular
to Linear Proportion; TPM, transcripts per million; PCA, Principal Component
Analysis; LFC, log2(Fold Change); ALL, Acute Lymphoblastic Leukemia.
for circRNAs in the regulation of cell proliferation and
leukemogenesis (Guarnerio et al., 2016; Sun et al., 2019; Yi et al.,
2019), in drug resistance (Shang et al., 2019b; Cao et al., 2020),
and as a diagnostic biomarker (Zhou et al., 2019) has been
reported. Furthermore, mounting evidence suggests a role as
potential therapeutic targets (Conn et al., 2015; Hirsch et al., 2017;
Wu et al., 2018b; Bell et al., 2019; Shang et al., 2019a,b).
In this study, we provide the first data on the circRNA
expression landscape in JMML patients identifying circMCTP1
ectopic expression as a new and possibly specific feature of
JMML, further complementing the molecular base of JMML
disease and paving the way to the identification of novel
biomarkers and therapeutic targets.
MATERIALS AND METHODS
Patients
Total RNA from diagnostic bone marrow (BM) or peripheral
blood (PB) samples from 31 children with JMML was obtained
from different institutions throughout Europe (Belgium,
Netherlands, France, Czech, and Germany). None of the patients
received prior treatment (Supplementary Table 1). Additionally,
BM and PB from pediatric healthy donors (HD); (siblings
screened for transplantation) were collected from 9 healthy
subjects at the Ghent University Hospital (Supplementary
Table 1). The “discovery cohort” used for RNA-seq profiling
comprised 19 JMML and 3 HD. Results were validated in an
additional cohort of 12 JMML patients and 6 HD. Out of 31
JMML patients, 15 are registered in the European Working
Group of Myelodysplastic Syndromes in Childhood (EWOG-
MDS) studies EWOG-MDS98 and EWOG-MDS2006 (National
Institutes of Health trials registered as #NCT00047268 and
#NCT00662090 at www.clinicaltrials.gov), and 16 in the French
national JMML biobank. Written informed consent was obtained
from the parents or legal guardians of patients before sample
collection and in accordance with the Declaration of Helsinki.
The study approval was granted from institutional review
committees at each participating center.
RNA Sequencing
Total RNA was extracted from isolated mononuclear cell
preparations from BM or PB from 19 JMML patients
(Supplementary Table 1), and 3 BM samples from HD.
RNA was extracted using the miRNeasy Mini or Micro Kit
(Qiagen) in combination with on-column DNase I digestion
(RNase-Free DNase set, Qiagen) according to manufacturer’s
instructions. RNA quality was assessed using the RNA 6000 Nano
and RNA 6000 PICO assays on a 2100 Bioanalyzer (Agilent).
Sequencing libraries were prepared using a TruSeq Stranded
Total RNA Kit adapted for long fragments (±550 bp) with the
Ribo-Zero Gold rRNA Removal Kit (Illumina) according to
the manufacturer’s instructions. Prepared libraries were run on
a HiSeq3000 high-throughput sequencing system (Illumina)
and paired-end reads were generated (average of 52 million
reads per sample).
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CircRNA Detection, Quantification and
Filtering
Circular RNAs were identified and quantified from RNA-seq data
by CirComPara v0.6.3 (Gaffo et al., 2017), using 9 backsplice
detection methods (Supplementary Material).
CircRNAs reported by at least two methods with a raw count
of at least five reads in at least one sample were considered
detected. Only circRNAs expressed in at least one half of samples
per condition (JMML and HD), or in over 3/4 of samples in at least
one JMML subgroup were kept for the following analyses.
CircRNAs annotation and all analyses were based on the
Ensembl GRCh38 human genome and annotation v93. Loci
without annotated genes and expressing one or more circRNAs
(overlapping or not far than 5,000 nt) defined new loci, called
“CircClust.” Exon numbers (respectively, to the longest Ensembl
transcript) are indicated in the circRNA names when multiple
isoforms from the same gene are mentioned or to identify
validated circRNAs.
Circular to linear proportion (CLP) was calculated as
described in Supplementary Material.
CircRNA Differential Expression
Circular RNAs expression was normalized with the regularized
logarithm method (Love et al., 2014), and the surrogate variables
were estimated with the sva R package (Leek, 2014) in order to
remove hidden batch effects.
Differential expression in pairwise comparisons between
conditions or sample groups was assessed by DESeq2 (Love et al.,
2014) (v1.22.2) with local fit model including Wald significance
tests, no independent filtering and correction for surrogate
variables. P-values were corrected for multiple tests with the
Benjamini Hochberg procedure, and an adjusted p-value ≤ 0.05
was chosen to detect significant differential expression.
CircRNA-miRNA-Gene Network
Reconstruction
Putative circRNA sequences were assembled joining annotated
exons contained in the genomic coordinates corresponding
to the validated backsplice ends. MiRNA binding sites were
predicted through miRanda (John et al., 2004) (score ≥ 100
and free energy ≤ −20 kcal/mol) and PITA (Kertesz et al.,
2007) (1Gduplex < −20 kcal/mol and 1Gopen > −13 kcal/mol),
keeping only miRNAs with commonly predicted binding sites.
MiRNAs were subsequently prioritized according to expression
in a published series of 21 JMML patients [GEO Series accession
number GSE71452 (Helsmoortel et al., 2016)]. For recently
identified miRNAs, not quantified in the series, at least three
predicted binding sites for the same circRNA were required.
Validated miRNA target genes (strong miRTarBase validation
categories) were retrieved by Mienturnet web tool (Licursi et al.,
2019). Gene expression of validated miRNA targets was obtained
through StringTie v1.3.3 implemented in CirComPara. Genes
with a mean TPM expression in JMML samples greater than 1
were considered expressed.
CircRNA-miRNA-gene networks were visualized using
Cytoscape v3.7.2.
Quantification of circRNAs by qRT-PCR
Synthesis of cDNA was performed after an additional in-
solution gDNase elimination step (Heat&Run gDNA removal
kit, ArcticZymes), using the 5x PrimeScriptTM RT Master Mix
(Takara Bio Europe S.A.S.). All qRT-PCR reactions were carried
out with custom designed primers (Supplementary Table 2)
in 96-well plates using the Takyon qRT-PCR MasterMixes for
SYBR assays (Eurogentec) on a Viia7 analyzer (ThermoFisher).
TBP, HPRT1 and GAPDH were used as internal reference
genes. Ct thresholds were automatically determined by the
QuantStudioTM Real-Time PCR Software and data analysis was
performed according to state-of-the-art methods. Briefly, Ct
values generated for each target were corrected for primer pair
efficiency and expressed as relative quantities (RQ). Normalized
relative quantities (NRQ) were calculated by normalizing RQ
values against the expression of housekeeping genes. Additional
details are available in Supplementary Material.
RESULTS
CircRNAs Expression in Patients With
JMML and Healthy Donors
A cohort of 19 JMML patients representing the four main
subtypes (8 PTPN11, 5 KRAS, 4 NRAS, and 2 NF1 samples;
Supplementary Table 1) was analyzed together with 3 age-
matched healthy donors (HD; GEO ID: GSE147523) to study
circRNA expression in patients with JMML.
Quantification and annotation of circRNAs, from high-depth
ribo-depleted RNA-seq data, by CirComPara (Gaffo et al., 2017)
detected 43,757 circRNAs, of which 5,323 with high expression
were considered for further investigation (see section “Materials
and Methods”). These circRNAs derived from 2,585 loci, mostly
from exonic regions (95.5%), followed by gene introns and
genomic regions without known genes (Figure 1A). Overall,
1,133 (43.8%) circRNA host genes expressed multiple circular
isoforms each, with 28 genes expressing 10 up to 23 isoforms
(Supplementary Figure 1 in Supplementary Material).
Clustering of circRNA expression profiles pointed toward
differences between JMML patients and HD, separating circRNAs
into two almost equally numerous groups of circRNAs with a
tendency of over and under expression in JMML (Figure 1B).
Considering the circular to linear proportion (CLP, giving
the relative expression of a circRNA in relation to the total of
overlapping circular and linear transcripts) we identified 118
circRNAs accounting for at least one third of the total expression
in JMML (CLP ≥ 0.33; Supplementary Table 3). Among the 30
with highest expression (Figure 1C), circCSNK1G3, circSCLT1
and circSWT1 were more abundant than their corresponding
linear counterparts (CLP > 0.5), in JMML.
CircRNAs Are Dysregulated in JMML
Circular RNAs expression profiles separated JMML samples from
HD according to unsupervised principal component analysis
(PCA; Figure 2A), pointing toward a general dysregulation of
circRNA expression in patients. Considerable heterogeneity was
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FIGURE 1 | CircRNAs expressed in BM of JMML patients and healthy subjects. (A) Proportion of circRNAs derived from genic and intergenic regions; (B) Heatmap
(row scaled values, clustering according to Euclidean distance) of normalized expression profiles of the 5,323 circRNAs considered in the study, corrected for
surrogate variables; (C) CircRNAs with CLP ≥ 0.33 and circular mean expression > 40 in JMML.
observed among JMML patients, and both PCA and clustering
(Figure 1B) showed that KRAS, NRAS, and PTPN11 mutated
patients clustered together, while the two NF1 samples clearly
separated from both HD and the other molecular groups.
Comparing JMML with controls, we identified 119 circRNAs
significantly differentially expressed (Figures 2B,C and
Supplementary Table 4). Of those, 37 circRNAs had different
expression levels in the entire JMML cohort compared to
HD. Pairwise comparisons of individual JMML subgroups
to HD revealed 29 circRNAs dysregulated in KRAS, 34
in NRAS, 7 in PTPN11 and 25 in NF1, with 11 circRNAs
dysregulated in two or three different JMML molecular
subtypes. None of the circRNAs significantly dysregulated
in PTPN11 patients had significantly altered expression
in one of the other three groups nor considering all
JMML samples together. Nevertheless, it could be observed
that several circRNAs significantly varied a single group
showed a similar trend of expression in other groups, as
exemplified by circKPNA5(3–12) which was significantly
down-regulated in NF1 samples while simultaneously showing
a generalized trend toward lower expression in the other
molecular groups.
Of the 119 differentially expressed circRNAs, 90 were up-
regulated in JMML compared to HD. Of these, 27 were identified
considering the entire JMML cohort and 63 considering each
subtype separately (Figure 2C). CircRNAs with a general marked
up-regulation (log2FoldChange, LFC > 15) included circPSEN1,
circCCAR1, and circMED13. In KRAS mutated JMML cases
compared to HD, 26 circRNAs were up-regulated, including
circPICALM, circTET2 and circZMYND11(2–4). In NRAS,
30 circRNAs were up-regulated, including circAFF2(2–3),
circMCTP1(9–12), and circNBPF25P(13–14). Interestingly,
circAGFG1, circHERC4, circPMS2P2, and circPI4KB were
not expressed in control samples, while being up-regulated
in the PTPN11 subgroup. In NF1, 11 circRNAs were up-
regulated, including circMAN1A2, circEMB and circSCLT1.
Finally, we identified five circRNAs up-regulated in both
KRAS and NRAS samples [circEMILIN2(4), circLRCH3,
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FIGURE 2 | Significantly differentially expressed circRNAs in BM of JMML patients compared to HD. (A) Principal Component Analysis (PCA) of circRNA normalized
expression profiles, corrected for surrogate variables; (B, C) Expression heatmaps of the 29 circRNAs down-regulated (B) and 90 up-regulated (C) in JMML.
Expression given as row scaled values. The first 5 bars on the left of the heatmap show Log2(Fold Change) (“Fold change”), and the second 5 bars the significance
of differential expression when comparing all JMML considered together and each JMML molecular subtype versus HD (“Significance”); “AE,” per row average of
absolute expression.
circLYN(5–8), circUBAP2, and circAFF2(3)], one in both
NF1 and NRAS (circFGD4), and two in both KRAS and NF1
(circDYRK1A and circVCAN).
We detected 29 circRNAs down-regulated in JMML, of which
10 considering the whole cohort [particularly circATM(2–8),
circPTPN22(8-intr14), and circLATS1(5–6)], and 19 considering
subgroups of JMML separately (Figure 2B). CircEXOC6B
turned out to be down-regulated in both comparisons. Three
circRNAs were mutually down-regulated in different molecular
groups: circATM(2–4) in KRAS, NRAS and NF1 samples,
circOXNAD1(7–8), and circESYT2(3–7) in both NF1 and NRAS.
CircX, derived from a gene in chromosome X likely expressing
only circular transcripts (Gaffo et al., 2019), and circCCDC7 were
down-regulated in KRAS. CircPCMTD1 was down-regulated in
NRAS, while circS100PBP, circACSF3 and circSORT1 were less
expressed in PTPN11 samples than HD. The highest number
of down-regulated circRNAs was observed in the NF1 subgroup
(N = 14) and included circEXOC6B.
Within the 119 differentially expressed circRNAs, we
identified 6 genes with multiple circular isoforms. CircATM(2–8)
was generally down-regulated in JMML, while circATM(2–
4) was weakly expressed in all JMML subgroups except in
PTPN11 samples. CircATG7(13–18) was up-regulated in
JMML altogether, circATG7(13–17) only in NRAS samples.
CircMCTP1(7) and cirMCTP1(9–12) were both up-regulated
in NRAS. Also, for AFF2 and LYN genes two overlapping
circular isoforms were identified: circAFF2(3) and circLYN(5–8)
were up-regulated in both KRAS and NRAS, circAFF2(2–3)
and circLYN(2–8) only in NRAS and KRAS, respectively.
Surprisingly, an isoform switch was observed for the DNA2
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gene with circDNA2(2–14) generally more expressed in HD and
circDNA2(2–5) isoform overexpressed in NRAS patients.
Genes With Imbalances of Circular and
Linear Transcripts in JMML
Beyond absolute dysregulation of circRNA expression, also
imbalances of circular and linear transcript expression in JMML
emerged. Sixty-one circRNAs showed high absolute expression
and varying CLP in JMML or in controls (Figure 3).
An increase of the CLP in JMML was observed for 18
circRNAs. This was due to a larger expression increase of
the circRNA than the linear counterpart [e.g., circFCHO2,
circEMILIN2(4), circAKAP7, circSWT1, and circTMEM56],
or to a decrease of the linear transcripts (e.g., circNUSAP1
and circMINPP1). The decrease of circANKRD36B with a
more marked decrease of the linear counterpart resulted in a
relative increase of this circRNA in JMML. For 53 circRNAs
the CLP decreased comparing JMML with HD, mostly due
to a concordant behavior of circular and linear transcripts,
with a more conspicuous decrease of the circRNA (e.g.,
circNFYB). CircEXOC6B was significantly down-regulated in
JMML, whereas the linear transcripts of its host gene were
unvaried, thus circEXOC6B CLP was higher in controls (0.62)
than in JMML (0.18). Additionally, the CLP decrease for
circNBPF14 in JMML reflected both a decrease of the circRNA
and a marked increase of the linear counterpart. Three circRNAs
had a very stable expression comparing JMML and controls, but
a varied CLP due to the increase (circEPSTI1) or to the decrease
(circCASP8AP2 and circCCDC7) of their linear counterpart.
Of note, 9 circRNAs significantly differentially expressed
in JMML (Figures 2B,C); the [up-regulated circEMILIN2(4),
circVRK1, circFGD4, and circRHBDD1, and the down-regulated
circNBPF14, circRASA2, circLCLAT1, circEXOC6B, and
circKPNA5(3–12)] compared with HD were among the 61
with more pronounced variation of CLP (Figure 3). The
altered expression of these circRNA did not co-occur with a
corresponding variation of the linear counterpart and reflects an
imbalance of the circular and linear products of the same gene.
CircRNA Dysregulation Confirmed in a
Validation Cohort
Next, we selected 27 circRNAs with dysregulated expression in
JMML patients for quantification in an independent validation
cohort of 12 JMML samples and 6 HD (Supplementary Table 2).
For all of the tested circRNAs the backsplicing sequence could
be confirmed by Sanger sequencing. For 20 circRNAs, qRT-PCR
quantification in the validation cohort strengthened our findings
(Supplementary Table 1 and Figure 4).
Of note, for 9 circRNAs, the significant dysregulation in
JMML patients observed by RNA-seq was confirmed in the
validation cohort. CircATM(2–4), circOXNAD1(7–8), and circX
were consistently down-regulated in JMML. CircCCAR1(12–14),
circMED13(2–8), circMCTP1(9–12), circLYN(5–8), circAFF2(3),
and circAFF2(2–3) were up-regulated. Most striking was
the >80 times up-regulation of circMCTP1(9–12) in JMML.
For five additional circRNAs, the same trend was observed
in the two cohorts, with expression differences resulting
marginally significant (0.05 < p.adj ≤ 0.1) in the validation
cohort: circLNPK(5–10), circNDEL1(2–8), circPSEN1(2–3), and
circAGFG1(2–5) showed a tendency toward up-regulation in
JMML, circPTPN22(8-intr14) toward a general down-regulation.
For the remaining 6 circRNAs, data of PCR-based quantification
showed the same trend of expression observed by RNA-seq,
without reaching the significance.
Expansion of the independent validation cohort with 9
patients from the discovery cohort with sufficient RNA available
for qRT-PCR, depicted comparable and stable results, confirming
the dysregulated expression of 15 circRNAs (Supplementary
Figure 2 in Supplementary Material).
As circRNAs are well-known for decoying miRNAs, we
evaluated the circRNA-miRNA-gene network for the five
most markedly dysregulated circRNAs [circMCTP1(9–12),
circAFF2(3), and circLYN(5–8) up-regulated; circATM(2–4) and
circOXNAD1(7–8) down-regulated] (Supplementary Figure 3
in Supplementary Material).
CircRNA Expression Variation in JMML
Molecular Subtypes
Although the cohort of samples in each subgroup was limited,
circRNA with expression differences among molecular subgroups
of JMML emerged from our data.
QRT-PCR validations of the panel of 20 circRNAs scrutinized
for differential expression in JMML suggested significant, even
if not sizable, variation of circRNA expression among groups
(Figure 5A and Supplementary Figure 4 in Supplementary
Material). CircMCTP1(9–12) and circMED13(2–8) up-
regulation was more marked in NRAS; circZMYND11(2–4) was
more expressed in NRAS than in KRAS samples; circESYT2(3–7)
showed down-regulation in PTPN11 compared to NRAS, and at
some extent also to KRAS; circEMILIN2(4) had a tendency of
up-regulation in KRAS compared to PTPN11 and circPTPN22(8-
intr14) was down-regulated in both KRAS and NRAS, but not in
PTPN11, compared to controls.
Following these observations, RNA-seq based direct pairwise
comparisons between groups identified 22 additional circRNAs
significantly varying between groups (Figure 5B). Apart from
circMYBL1, which showed significantly lower expression in
PTPN11 compared with KRAS, all the other circRNAs (7 up-
regulated and 14 down-regulated) significantly varied between
NF1 patients and the other groups. Noteworthy, circVCAN was
significantly more expressed in NF1 compared with PTPN11,
and significantly up-regulated comparing NF1 and KRAS JMML
subtypes with HD (Figure 2).
CircMCTP1 Dysregulation in JMML
CircMCTP1(9–12) was found to be highly up-regulated in JMML
compared with HD (Figure 4 and Supplementary Figure 2)
and with higher levels observed in NRAS patients, consistently
according to RNA-seq (Figure 2C) and qRT-PCR data in the
extended cohort (Figure 5A).
CircMCPT1 dysregulation is a completely new finding and
the function of this circRNA is still unknown. Considering
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FIGURE 3 | Circular to linear proportion (CLP) dysregulated in JMML compared to healthy donors. The 61 circRNAs with high absolute expression (normalized read
count ≥ 100) and CLP (≥0.1) in JMML or HD for which the proportion of circular expression over the total (linear and circular) expression in JMML was at least two
times increased or decreased compared to HD (|LFC(CLP)| ≥ 1). The plot shows the LFC observed comparing JMML with HD absolute linear and circular
expressions (blue and pink bars, respectively) and CLP (dashed gray line). HD, healthy donors; LFC, log2(Fold Change).
that one of the prominent functions assigned to circRNAs
is to decoy miRNAs thus interfering with they regulatory
activity, we further investigated the possible interactions
of circMCTP1 with miRNAs, and reconstructed circRNA-
miRNA-gene networks that informed the possible function of
circMCTP1 in JMML.
Interestingly, circMCTP1 harbors predicted binding sites for
well-known tumor suppressor miRNAs (Figure 6A), including
miR-8075 (Song et al., 2019) for which four binding sites
were found in the circRNA sequence, and several miRNAs
known to be expressed in JMML according to Leoncini
et al. (2016). Further, consistent with the hypothesis that
circMCTP1 aberrant up-regulation could de-repress specific
miRNA-target genes in malignant cells, our analysis of RNA-
seq gene expression data in the discovery cohort identified
increased expression in JMML of validated targets of circMCTP1-
associated miRNAs. Particularly, 32 target genes of miR-138-5p,
miR-638 (Lin et al., 2015), miR-508, and miR-572 had increased
expression in JMML, including eight that also showed, in JMML
patients, an expression profile strongly positively correlated
(ρ ≥ 0.4) with circMCTP1 expression (Figure 6B). These data
pointed at possible regulatory axes impacted by circMCTP1 up-
regulation.
DISCUSSION
Knowledge of circRNA involvement in pathogenetic mechanisms
of cancer (Kregel et al., 2019) and leukemia, such as AML
(Guarnerio et al., 2016; Sun et al., 2019; Yi et al., 2019) and
acute lymphoblastic leukemia (ALL) (Hirsch et al., 2017; Gaffo
et al., 2019; Molin et al., 2019) (make circRNAs extremely
attractive molecules for translational research in oncohematology
(Bonizzato et al., 2016; Kristensen et al., 2018)). In this
study we used total RNA sequencing to uncover the circRNA
transcriptome in 19 JMML patients of four molecular subtypes
and their potential role in JMML disease.
We showed that JMML samples like all other human tissues
studied so far possess a wide array of circRNAs and more
importantly, that the circRNAome is altered comparing JMML
patients to HD. In total, 119 circRNAs were differentially
expressed of which 37 significantly taking all JMML samples
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FIGURE 4 | CircRNA differential expression validations. QRT-PCR quantifications of 20 circRNAs, with differential expression between JMML and HD according to
RNA-seq data, were obtained in the validation cohort comprising 12 JMML (red dots) and 6 age-matched HD samples (green dots). CircRNA quantification in not
less than 8 patients was obtained for all the circRNAs; p-values (two-tailed) were calculated by the Mann–Whitney U test.
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FIGURE 5 | CircRNA expression variation in molecular subtypes of JMML. (A) QRT-PCR expression data of 6 circRNAs in 21 JMML of 5 molecular subtypes [KRAS,
NRAS, PTPN11 and NF1 mutated, and quintuple negative (5N)], and 6 age-matched HD samples. CircRNA quantification in not less than 17 patients was obtained
for all the circRNAs; differential expression of KRAS, NRAS, and PTPN11 groups compared with HD (Kruskal–Wallis test) and to each other was tested with
Mann–Whitney U test; only p-values < 0.1 are shown for the corresponding pairwise comparison. (B) Expression heatmap of circRNAs differentially expressed
between JMML molecular subtypes according to RNA-seq data (sample expression is given as row scaled values). The first group of bars on the left of the heatmap
show Log2(Fold Change) comparing KRAS, NRAS, and PTPN11 groups to each other and with HD (“Fold change”); the second group of bars show the significance
of differential expression in pairwise JMML subgroups comparisons (“Significance”); “AE,” per row average of absolute expression.
together and 83 when comparing each molecular subtype with
HD (29 dysregulated in KRAS, 34 in NRAS, 7 in PTPN11 and 25
in NF1).
A few circRNAs dysregulated in JMML were reported earlier
as aberrantly expressed in other types of cancer. Down-regulation
of circEXOC6B in JMML, particularly in NF1 patients, had been
detected in epithelial ovarian cancer in association with a lower
survival rate (Ning et al., 2018). Up-regulation in JMML of the
oncogenic circHIPK3 (Zheng et al., 2016; Chen et al., 2020) is in
line with reported overexpression in B-cell precursor ALL (Gaffo
et al., 2019) and in chronic myeloid leukemia (Feng et al., 2020).
Two other circRNA up-regulated in JMML were linked to breast
cancer, circIRAK3 (Wu et al., 2018a) and circEPSTI1 (Chen
et al., 2018). The latter and circMAN1A2 (Fan et al., 2019) were
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 January 2021 | Volume 8 | Article 613540
fcell-08-613540 December 21, 2020 Time: 14:25 # 10
Dal Molin et al. CircRNAs in Juvenile Myelomonocytic Leukemia
FIGURE 6 | Predicted circMCTP1-miRNA-gene network. (A) CircMCTP1 (red circle) is linked to miRNAs (diamonds) according to binding sites predicted by both
miRanda and PITA tools; names in bold and blue indicate, respectively, miRNAs expressed in JMML (Leoncini et al., 2016) and with tumor suppressor role according
to literature data; recently identified miRNAs with at least three predicted binding sites are also reported; size of circMCTP1-miRNA edges is proportional to the
number of the predicted binding sites for that miRNA (range 1–4); validated miRNA target genes resulting from Mienturnet (strong MiRTarBase categories) are shown
as squares, with fill color indicating the LFC of the gene expression variation comparing JMML with HD. (B) In JMML patients expression of eight genes in the
network was strongly correlated (ρ ≥ 0.4) with circMCTP1 level.
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previously proposed as biomarkers of malignancy. CircDYRK1A
down-regulation, observed in JMML, was found in plasma of
patients with gastric cancer (Chen et al., 2017). Additional
studies are needed to prove, in JMML, the oncogenic role of
these and other still less characterized circRNAs that resulted
dysregulated in our data.
Robust evidence about dysregulation of 15 circRNAs
was obtained by analysis of two independent cohorts.
CircOXNAD1(7–8) and circATM(2–4) were consistently
down-regulated in JMML patients compared to HD in the two
cohorts. CircOXNAD1(7–8) was previously shown to be more
expressed in monocytes compared with lymphocytes (Gaffo et al.,
2019). CircATM(2–4), derived from the ATM gene, encoding a
protein important for DNA repair whose mutations are found
in myeloid malignancies (Ganguly and Kadam, 2016), was the
most abundant circRNA in BM of healthy donors and showed a
generalized down-regulation in JMML.
CircMCTP1(9–12), circLYN(5–8), and circAFF2(3) were the
most highly up-regulated circRNAs in JMML. None of these had
been heretofore identified in a myeloid malignancy. CircAFF2(3)
is overexpressed also in B-cell precursor ALL (Gaffo et al.,
2019). In the same study, we have shown that, in normal
haematopoiesis, both circMCTP1(9–12) and circAFF2(3) are
up-regulated in monocytes compared to lymphocytes, whereas
circLYN(5–8) is highly expressed both in monocytes and
B-cells. Of note, up-regulation in JMML of circMCTP1(9–12),
circLYN(5–8), and circAFF2 isoforms was not associated with
a comparable increase of the linear counterpart: their CLP
increase in JMML indicated that the circRNA variation was
not a mere consequence of up-regulation of the corresponding
host genes. This study identified, nevertheless, specific genes
with an imbalance of circular and linear transcripts in
JMML, detecting circRNAs with CLP variation in JMML
compared with controls, such as the increase of circFCHO2
and circSWT1 and the decrease of circNBPF14 CLP. Of
note, we discovered that nine of the circRNAs significantly
differentially expressed in JMML presented also an imbalance
of the circular and linear products of the gene. Regulation of
circular RNA expression independent of linear expression is
mainly uncharted territory. Our observations support the view
that abnormal circRNA expression is often independent of linear
expression variation.
Our finding of strong circMCTP1(9–12) up-regulation
in JMML is completely new and constitutes an important
highlight of this study. To our knowledge, circMCTP1(9–12)
was not previously characterized nor reported. The host
gene MCTP1 (mast cell protease 1) has not been associated
with hematological or solid malignancies. CircMCTP1(9–12)
expression is potentially important for JMML pathogenesis
and calls for further research. Functional predictions and
gene expression data provided a first look at the complex
circRNA-miRNA-gene networks that might contribute to JMML
disease. CircRNA up-regulation was previously shown to restrain
miRNA activity causing de-repression of miRNA target genes
(Memczak et al., 2013; Shang et al., 2019b). In particular,
predictions point at circMCTP1 potential to decoy tumor
suppressor miRNAs expressed in JMML (Leoncini et al., 2016):
miR-138-5p (Manafi Shabestari et al., 2018; Rastgoo et al., 2018),
miR-638 (Lin et al., 2015), miR-508-5p (Chan et al., 2016), miR-
572 (Guan et al., 2018), and miR-8075 (Song et al., 2019)
for which four binding sites were predicted and for which
sponging by circular or linear transcripts has been recently
linked to cancer development (Song et al., 2019). Furthermore,
amongst the validated target genes of circMCTP1 associated
miRNAs, we identified genes with increased expression in
JMML. These include the ZEB2 transcription factor essential for
maintenance of leukemic growth in AML (Li et al., 2017), LCN2
lipocalin whose ectopic expression promotes leukemogenesis
(Chakraborty et al., 2012), and other genes previously linked to
AML (RARA, CCND1, and NFKB1). In addition, up-regulated
genes of the RAS signaling pathway (IGFR1, NFKB1, and
PLD1), of the PD-L1 expression and PD-1 checkpoint pathway
(HIF1A, LCN2, and NFKB1), and of the HIF-1 signaling pathway
(HIF1A and NFKB1) were conspicuous in the circMCTP1
network. Among genes further highlighted by the observation
of an expression profile, in JMML patients, positively correlated
with circMCTP1 expression, GNAI2, PLD1, ADGRA2, MXD1,
VIM, and MAP3K11 are particularly noteworthy. In conclusion,
analysis of networks linked ectopic circMCTP1 expression in
JMML to miRNAs and to up-regulated target genes with
oncogenic associations, suggesting new regulatory axes.
Our aim was to provide an overview of circRNA dysregulation
in JMML. This knowledge is entirely new to the field and
represents the starting point for further studies. We suggest that
experimental studies are needed to clarify the functional roles of
circRNAs in JMML and to shed light on involved mechanisms.
Evidence collected by our analyses informed circRNA expression
variation between JMML molecular subtypes and contribution
to disease heterogeneity. On the level of circRNA expression,
the NF1 subgroup is more divergent from the other subgroups,
in line with data about lncRNAs (Hofmans et al., 2018).
This observation, and more subtle differences between PTPN11
compared with KRAS and NRAS, calls for further investigation
in larger cohorts, with also the potential to inform association
of circRNA expression with biological and clinical features of
patients, useful to establish new biomarkers in JMML. Finally,
we propose that our data can pave the way to novel therapeutic
strategies, possibly targeted to circRNA-involving mechanisms,
for instance by implementing in vivo circRNA silencing strategies
(Holdt et al., 2018).
In conclusion, we performed a comprehensive circRNA
profiling in JMML, and demonstrated that JMML patients
harbor a distinct circRNA expression profile compared to healthy
controls. Dysregulation of known and many unknown circRNAs,
such as circMCTP1, suggests a role for circRNAs in JMML
pathogenesis, and results of functional predictions give insights
in the genes and biological pathways involved. This study offers a
new view in JMML and paves the way for functional research on
the impact of circRNAs dysregulation in JMML biology and their
diagnostic and therapeutic application.
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